News and Events

Video Blog – SENSITIVITY, SCALABILITY AND SPEED: The Value of Next Generation Sequencing (NGS) for Identity Testing of Plasmids & Viral VectorsIdentity testing is critical for ensuring quality and safety of biopharmaceuticals. As such, identity testing is a key...

PathoQuest Reiterates its Strategic Growth Plans by Appointing Daniel Spasic to the BoardDaniel Spasic, a highly experienced lifescience business leader, has been appointed as a non-executive director to the board of PathoQuest.  With over 25 years of hands-on...

PathoQuest Announce the Opening of its New U.S. Facility The Leading Experts in NGS Biosafety Testing and Characterization of Biopharmaceuticals Launch New Capabilities in the Critical U.S. Market Wayne, PA, and Paris, France – October 4, 2022 – PathoQuest, a leader...

A Podcast from Transgene: NGS-Based Biosafety Strategy for Breakthrough Virus-Based Immunotherapies Transgene is a French biotech developing virus-based immunotherapies. There manufacturing processes deal with breakthrough therapeutic vaccines highly awaited by...

PathoQuest Appoints Rainer Metzger, Ph.D. as Chairman of the Board of DirectorsPARIS, FRANCE – September 1st, 2022 – PathoQuest, a pioneer of next-generation sequencing (NGS)-based testing solutions for the quality control of biologics, today announced the appointment...

PathoQuest Announces Appointment of Michael Mellor-Clark as Chief Commercial Officer PARIS, FRANCE, June 23, 2022 – PathoQuest, a leading Contract Research Organization (CRO) for the biosafety testing of biologics with Next-Generation Sequencing (NGS) technologies,...

PathoQuest Appoints Sébastien Renouf, Pharm D., as Chief Pharmaceutical Officer Dr. Sébastien Renouf has almost 20 years of experience in Regulatory Affairs, Risk Management, Quality Assurance, and Safety Control for Cell & Gene Therapy.  Before joining...

PathoQuest Appoints Eric Cazergue as Chief Financial Officer PARIS, FRANCE — April 06, 2021 – PathoQuest, a pioneer of Next Generation Sequencing (NGS)-based testing solutions for the quality control of biologics, today announced the appointment of Eric Cazergue as...

PathoQuest Appoints Colette Côté as Chief Portfolio Officer and General Manager of the Company’s U.S. Subsidiary WAYNE, PA, and PARIS, FRANCE – March 18, 2021 – PathoQuest, a pioneer in the development and application of novel Next Generation Sequencing (NGS)-based...

PathoQuest Appoints Guillaume Deplaine, Ph.D., as Head of Operations Dr. Guillaume Deplaine has 10 years of experience in the Biotechnology industry. Prior to joining PathoQuest, Dr. Deplaine was the Quality Control and Analytical Development Head at CELLforCURE a...